lamivudine / zidovudine

This medicine is authorised for use in the European Union.


This is a summary of the European Public Assessment Report (EPAR) for Combivir. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Combivir.

For practical information about using Combivir, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 29/08/2022

Authorisation details

Product details
Agency product number
Active substance
  • lamivudine
  • zidovudine
International non-proprietary name (INN) or common name
  • lamivudine
  • zidovudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
ViiV Healthcare BV
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Van Asch van Wijckstraat 55H
3811 LP Amersfoort
The Netherlands

Product information

11/08/2022 Combivir - EMEA/H/C/000190 - IG1532

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection.

Assessment history

How useful was this page?

Add your rating